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Signal transduction pathways commonly go awry in cancer. Recent advances in understanding how these pathways
contribute to tumor formation are the focus of this issue’s Cancer Biology Select. New studies use RNAi-based screens
and powerful mouse models to pull out critical factors essential for the survival of lung cancer cells. Other discoveries
include a chemical-genomics approach to screen for drug efficacy, surprising crosstalk between two previously uncon-
nected signaling pathways, and important implications for mobilization of tumor cells during metastasis.
Cutting off a Tumor’s Molecular Life Preserver
How do you target oncogenes that promote tumor growth and survival and are resistant to standard molecular-based ther-
apeutic approaches? One way is to ignore the oncogene and to go after themolecular life preservers that keep the tumor cells
alive. Barbie et al. (2009) take a step in this direction by performing a large-scale RNA interference (RNAi) screen to identify
genes that, when silenced, result in death of tumor cells expressing oncogenic KRAS. Following computational enrichment
strategies and a secondary screen using additional KRAS tumor cell lines, the authors pulled out a winner: the noncanonical
IkB kinase, TBK1, a key member of the NF-kB signaling pathway. Suppression of TBK1 induced apoptosis of tumor cells
expressing oncogenic KRAS. Meanwhile, transcriptional profiling of cells expressing oncogenic KRAS not only identified
the standard gene expression ‘‘signature’’ induced by KRAS but also pinpointed several genes associated with NF-kB
pathway activation. Likewise, a majority of lung adenocarcinomas isolated from cancer patients exhibited activation of
both KRAS and NF-kB gene expression signatures. Next, the authors identified the antiapoptotic gene BCL-XL as a potential
downstream mediator of TBK1’s action and a contributor to the survival of tumor cells expressing oncogenic KRAS. These
findings set the stage for testing the effects of blocking TBK1 action on tumor survival and open the door to targeting other
members of the NF-kB pathway for the treatment of lung tumors and other tumors that express oncogenic KRAS. In addition,
such an RNAi-based approach could be useful for identifying other players that promote KRAS tumor survival and could be
extended to tumors expressing other oncogenes.
D.A. Barbie et al. (2009). Nature. Published online October 21, 2009. 10.1038/nature08460.
NF-kB: A Key Player in Lung Cancer
In a related study, Meylan et al. (2009) also identify the NF-kB signaling pathway as a key
requirement of lung adenocarcinoma development in a mouse model of the disease. Despite
previous links between activation of NF-kB signalling and cancer cell survival, the precise role
of NF-kB in development and maintenance of tumors in vivo is unclear. By examining mouse
embryonic fibroblasts that express an oncogenic KRAS allele (that is activated by Cre)
combined with loss of the tumor suppressor protein p53, the authors observed increased
accumulation of the NF-kB transcription factor subunit p65 in the nucleus of these cells.
When they restored p53, the levels of p65 in the nucleus went down as did expression of the
NF-kB target gene Tnf. To examine the in vivo relevance of these findings, the authors com-
mandeered the conditional compound knock-in ‘‘KP’’ mouse, which expresses an activatable
oncogenic KRAS allele in combination with loss of p53. If the authors blocked NF-kB expres-
sion as tumors started to form, the KP mice ended up with remarkably few tumors. When they
blocked NF-kB expression only after tumor formation had already begun, the tumors were very
slow growing. The next step was to determine how NF-kB inhibition prevents tumor formation,
but the results of the gene expression analyses were somewhat surprising: expression of NF-kB gene targets known to inhibit
apoptosis was not significantly altered, whereas expression of inflammatory genes
such as Tnf and IL6 increased. As connections between inflammation and tumor
formation are emerging from other studies, the relevance of inflammation for tumor
formation in this system will need to be further investigated. Together with the Barbie
et al. results, the identification of NF-kB signaling as a determinant of KRAS-driven
tumor formation may lead to new therapeutic strategies to target the ‘‘undruggable’’
oncogene KRAS.
E. Meylan et al. (2009). Nature. Published online October 21, 2009. 10.1038/
nature08462.
Double Knockout in Cancer Therapeutics
A goal of cancer therapy is to predict better strategies to target tumors in which the
genetic mutation is already known. To this end, Sos et al. (2009) use a chemical-geno-
mics screen to assess the effects of single versus combined drug treatments in block-
ing key signal transduction pathways downstream of activated oncoproteins. Using
a panel of well-characterized non-small-cell lung cancer cell lines, the authors
measured cell death when either the PI3K or MAPK pathway was inhibited. Tumor
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cells with activating receptor tyrosine kinase mutations were more susceptible to inhibition of the PI3K pathway, whereas
tumor cells with activating RAS/RAF mutations grew despite inhibition of the PI3K pathway. Intriguingly, in the tumor cells
with activating tyrosine kinase mutations, blocking PI3K signaling resulted in activation of the MAPK pathway. This suggests
interplay between the PI3K and MAPK signaling pathways. Similar results were obtained when the tumor cells were trans-
planted into nudemice (which cannot mount an immune response against the tumor) and the mice were treated with an inhib-
itor of the PI3K pathway. When the authors then performed the screen using a selective MEK1/2 inhibitor that blocks the
MAPK pathway, BRAF and NRAS mutant cells were more susceptible to cell death, although the MAPK inhibitor now acti-
vated the PI3K pathway. Combined inhibition of both PI3K and MAPK pathways resulted in increased cell death of tumor
cell lines expressing mutant receptor tyrosine kinases or RAS/RAF. One implication of these findings is that, in contrast to
the prevailing view, it is the PI3K pathway that is the primary downstream pathway of cancer cells with mutant receptor tyro-
sine kinases, with MAPK activation as a secondary effect. This has implications for future therapeutic strategies for treating
tumors driven by receptor tyrosine kinases or RAS/RAF mutations. The authors suggest that intermittent high doses of drug
combinations that target both pathwaysmight bemore effective than low levels of a single drug that blocks only one pathway.
Sos et al. (2009). Proc. Natl. Acad. Sci. USA 106, 18351–18356.
More than One Path to the Nucleus
Recent findings now provide further tantalizing connections between two signal transduction pathways, Wnt and EGFR.
b-catenin is a component of cell-cell adhesion complexes as well as a key player in the Wnt/Wingless signaling pathway.
Upon Wnt activation, stabilized b-catenin translocates to the nucleus and upregulates key target genes. Ji et al. (2009)
now show that b-catenin canmake its way to the nucleus via a surprising new route that depends on activation of the receptor
for the EGF growth factor (EGFR). Previous studies indicated that mutations in Wnt pathway components can result in the
stabilization and transactivation of b-catenin, and these mutations are implicated in many human cancers. But b-catenin
also can be routed to the nucleus in the absence of Wnt signals or mutations, and, curiously, addition of EGF to tumor cells
leads to more b-catenin in the nucleus. Ji and coworkers report that activation of the EGFR pathway results in disruption of
a complex between b-catenin and one of its partners in adhesion, a-catenin. They go on to identify the series of events leading
up to this dissociation—an EGFR-ERK-CK2-mediated phosphorylation cascade that culminates in phosphorylation of a-cat-
enin and finally dissociation and transactivation of b-catenin. Upregulation of this pathway promoted tumor cell invasion and
correlated with malignancy in human glioblastoma samples, demonstrating the potential importance of this pathway in tumor
formation and progression. It will be interesting to examine whether EGFR-triggered b-catenin dissociation from a-catenin at
the plasma membrane might affect the formation of adherens junctions between cells and cell-cell adhesion. Further eluci-
dation of the complexities of EGF and Wnt pathway crosstalk might shed light on the pathogenic mechanisms of tumor
cell invasion and metastasis.
Ji et al. (2009). Mol. Cell 36, 547–559.
TGF-b Bumpstarts Breast Tumor Cell Metastasis
Further insights into how signaling pathways contribute to cancer cell motility and
metastasis are presented in recent findings by Giampieri and colleagues. An impor-
tant question in metastasis is how cancer cells become motile and leave the primary
tumor. Cancer biologists think that localized, transient changes in signaling pathways
might be responsible, andmeanwhile, imaging studies reveal that only a small number
of tumor cells are motile. Using intravital imaging, Giampieri et al. (2009) now pinpoint
variations in TGF-b signaling as a key factor determining the behavior of dissemi-
nating mammary tumor cells. The authors find that TGF-b signaling is transiently
active in single motile breast tumor cells but not in the tumor cells that are moving
along in cohesive groups. They then show that a TGF-b-driven transcriptional
program is required for switching cells from cohesive to single motile units. The
authors then investigate how migration of single cells compared to cell groups trans-
lates into metastasis. When TGF-b expression is blocked, collective migration of
breast tumor cells and invasive ability are associated with the capacity to gain entry
to the lymphatic system. When TGF-b is hyperactivated, single motile tumor cells
are able to gain entry to the blood system. Interestingly, it seems that cancer cells
cannot multitask because although TGF-b promotes entry into the blood, it reduces
proliferation. Therefore, turning off TGF-b signaling is important for the renewed
growth of breast tumor cells in the lung. As TGF-b signaling is not sufficient to initiatemotility of cancer cells, it will be important
to identify other factors involved in this process. Although targeting TGF-b has already been considered as a candidate ther-
apeutic approach in preventing metastasis, these findings indicate the complex effects of simply blocking TGF-b activity.
Giampieri et al. (2009). Nat. Cell Biol. Published online October 18, 2009. 10.1038/ncb1973.
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